ReviewFrontiers in cellular and infection microbiology2026
Overcoming multidrug resistance: antimicrobial peptides as a next-generation therapeutic strategy.
Review in Frontiers in cellular and infection microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Nature-inspired biomaterial innovations to counter medical device-associated infections.Biomaterials science · 2026Review
- Antimicrobial and Antibiofilm Activities of Glycyl-Histidine and Methionyl-Glycine Dipeptides: In Vitro and Molecular Docking Studies.Molecules (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Amidst the escalating global threat of antibiotic resistance, there is an urgent need for novel antibacterial agents with distinct mechanisms of action to address the impending post-antibiotic era. Antimicrobial peptides (AMPs), membrane-active peptides characterized by rapid bactericidal effects, broad-spectrum activity, and low resistance development potential, are considered promising candidates for overcoming the current multidrug resistance (MDR) crisis. However, the clinical application of AMPs is significantly limited by inherent drawbacks, including susceptibility to proteolytic degradation, poor oral bioavailability, potential mammalian cytotoxicity, low
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.